Status:
UNKNOWN
Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
Lead Sponsor:
Augusta University
Conditions:
Psychosis
Substance Use Disorders
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this trial is to determine if patients with comorbid psychotic disorder and substance use disorder will continue in treatment longer if treated with clozapine than with olanzapine, and ...
Eligibility Criteria
Inclusion
- 18-60 years of age, male or female (post-menopausal, surgically sterilized, or receiving either one of the listed contraception - depot contraceptive, Intrauterine device, or implanted hormonal contraceptive),
- who meet DSM-V criteria for schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, depression with psychotic features, or delusional disorder, and have ratings of Moderate or greater on at least one of the Brief Psychiatric Rating Scale psychosis items,
- who meet DSM-V criteria for at least one of alcohol, marijuana, cocaine, stimulant, or opioid use disorder, and have an admission urine drug screen positive for at least one of these substances,
- who have a stable living situation (family or supervised living, e.g. personal care home) to return to after release into the community,
- and who provide signed informed consent to participate (after testing for comprehension).
Exclusion
- Prior failure to respond or tolerate clozapine or olanzapine
- Logistics that prevent outpatient follow-up at Serenity Behavioral Health Adult Outpatient services
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03857581
Start Date
July 1 2020
End Date
July 1 2021
Last Update
March 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sandarsh Surya
Evans, Georgia, United States, 30809